Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefadroxil plus tyrosine kinase inhibitor in minimal residual disease-positive chronic phase CML (Cefadroxil trial)
jRCTs061180073Completed
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cefadroxil in chronic myeloid leukemia (CML). Primary endpoint: Overall response rate. Started Jun 2017; status: completed.
02
Drugs
cefadroxil
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on jRCTs061180073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180073.